US Patent

US9593099 — Compounds and compositions as protein kinase inhibitors

Composition of Matter · Assigned to Array Biopharma Inc · Expires 2030-08-27 · 4y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a novel class of compounds that inhibit protein kinase activity, particularly in diseases involving abnormal B-Raf activation.

USPTO Abstract

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

Drugs covered by this patent

Patent Metadata

Patent number
US9593099
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-08-27
Drug substance claim
Yes
Drug product claim
No
Assignee
Array Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.